SCHEMBL1482886

SCHEMBL1482886

N#Cc1ccc(CCc2cc(Cl)ccc2-c2nc3cc(F)c(F)cc3n2CC2CCCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 5/20 0.46
ALOX5 P09917 2/20 0.42
CTSS P25774 4/20 0.40
CTSL P07711 3/20 0.40
CTSK P43235 2/20 0.40
CNR2 P34972 4/20 0.40
KCNH2 Q12809 2/20 0.36
HTR2A P28223 2/20 0.35
HTR2C P28335 2/20 0.35
SLC6A4 P31645 2/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP11B1 P15538 1/20 0.35
CYP11B2 P19099 1/20 0.35
CYP3A4 P08684 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1482732 0.89 CNR2 (0.42) NR1H4ALOX5CNR2KCNH2MEN1
SCHEMBL1482352 0.88 ALOX5 (0.43) ALOX5CTSSCTSLCTSKCNR2
SCHEMBL1482661 0.87 NR1H4 (0.44) NR1H4ALOX5CTSSCTSLCTSK
SCHEMBL1482444 0.85 NR1H4 (0.45) NR1H4ALOX5CTSSCTSLCTSK
SCHEMBL1483118 0.84 NR1H4 (0.47) NR1H4ALOX5CTSSCTSLCTSK
SCHEMBL1482952 0.82 NR1H4 (0.51) NR1H4ALOX5CNR2KCNH2MEN1
SCHEMBL1482050 0.80 NR1H4 (0.44) NR1H4ALOX5CTSSCTSLCTSK
SCHEMBL1482276 0.79 NR1H4 (0.43) NR1H4ALOX5KCNH2HTR2AHTR2C
SCHEMBL1482770 0.79 KCNH2 (0.41) NR1H4KCNH2SLC6A4CYP11B1CYP11B2
SCHEMBL1482246 0.79 NR1H4 (0.55) NR1H4ALOX5CNR2KCNH2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8309581-B2 Benzimidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2012-11-13 US disclosed
EP-2483247-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. Hoffmann-La Roche AG (CH) 2012-08-08 EP disclosed
WO-2011039130-A1 NEW BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS FXR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2011-04-07 WO disclosed
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2011-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110077273-A1 NEW BENZIMIDAZOLE DERIVATIVES BRI3BP, CYP3A4, RB1 NR1H4 776/4885ALOX5 3919/4885CTSS 1909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.